Global Liver Institute

Liver Health Policy

GLOBAL LIVER INSTITUTE

Liver Health Policy

Policy Agenda

GLI advocates for the elevation of liver health to its rightful place on the global public health agenda commensurate with its prevalence and impact.

GLI engages with

Court

U.S. Federal Agencies: CMS, CDC, NIH, NIDDK, VA, & more

Congress

U.S. Congress

Global

Global Health Agencies: WHO, EMA, & more

Priority Initiatives

COVID-19 Response

COVID-19 Response: Ensure that people living with liver disease are not disproportionately impacted by COVID-19 and do not experience unnecessary or discriminatory health care or treatment disruptions

Health Disparities

Health Disparities: Address inequities in the care of people impacted by liver disease

Liver Health Policy

Liver Health Policy: Advance Liver Health is Public Health globally, the U.S. NASH Action Plan, and policies that prevent and address the more than 100 types of liver diseases and related conditions

Liver Health Regulations

Liver Health Regulations: Work with regulators to better incorporate the experiences, perspectives, and needs of liver patients into regulatory decision-making

Engaged Initiatives

Liver Health Research

Liver Health Research: Advocate for funding that ensures meaningful growth of vital liver health research and public health programs

Transplant

Transplant: Urgently respond to the inequities that impact organ transplantation; improve care for transplant patients, and increase the number of available organs

Viral Hepatitis

Viral Hepatitis: Increase support for hepatitis programs and raise awareness of viral hepatitis; advocate for the the elimination of viral hepatitis

Value

Value: Advance health care policies that reflect the unique ability patients have to contribute to the understanding of their condition and treatment management

Patient Access and Reimbursement

Patient Access and Reimbursement: Support policy solutions that curb patients’ health care expenses, and protect access to transformative therapies

Take Action

Co-Sponsor the Liver, Illness, Visibility, Education, and Research (LIVER) Act 2021 (H.R. 5675)

Co-Sponsor the Medical Nutrition Equity Act (H.R. 3783)

Co-Sponsor the Multi-Cancer Early Detection Screening Coverage Act (S. 1873)

Co-Sponsor the Treat & Reduce Obesity Act (S. 596)

Co-Sponsor the Safe Step Act (S. 464)

General Rare Disease Info
Closeup Of Business Woman Making Notes In Document

Policy Highlights

8

Leading multiple Virtual Liver Advocacy Days and Congressional Briefings that educate policy makers about liver health

8

Urging regulators to support additional COVID-19 vaccine doses for immunocompromised individuals

8

Working with the U.S. Congress to reform the Organ Transplant System, advance patient centric legislative packages, and introduce liver specific bills like the LIVER Act, and the NASH Care Act

Externally-Led Patient-Focused Drug Development Meetings

Externally-Led Patient-Focused Drug Development (EL-PFDD) Meetings are held to systematically obtain the patient perspective on specific decisions and their treatments to provide context for regulatory decisions for new drugs. GLI holds EL-PFDD meetings with key partners to promote patients’ perspectives as pharmaceutical solutions for liver diseases are developed.